Physical Trauma

Selected References:

- Brown S, Mozurkewich E. 2013. Trauma during pregnancy. Obstet Gynecol Clin North Am, 40(1):47-57.
- Cahill AG, et al. 2008. Minor trauma in pregnancy–is the evaluation unwarranted? Am J Obstet Gynecol, 198(2):208.e1-5. Colantonio A, Mar W, Escobar M, Yoshida K, Velikonja
- D, Rizoli S, Cusimano M, Cullen N. 2010. Women's health outcomes after traumatic brain injury. J Womens Health (Larchmt), 19(6):1109-16.
- Dalton SE, et al. 2023. Major trauma in pregnancy: prediction of maternal and perinatal adverse outcomes. Am J Obstet Gynecol MFM, 5(9):101069.
- Dina EK. 2004. Trauma during pregnancy: An analysis of maternal and fetal outcomes in a large population, Am J Obstet and Gynecol, 190, 1661-1668.
- Dorairaj J, et al. 2012. Delayed presentation of intraperitoneal bladder rupture following domestic violence in pregnancy. J Obstet Gynaecol Res, 38(4):753-6.
- Fabricant SP, et al. 2021. Trauma in pregnancy and severe adverse perinatal outcomes. J Matern Fetal Neonatal Med, 34(18):3070-3074.
- Hattori S, et al. 2021.Factors Influencing Pregnant Women's Injuries and Fetal Loss Due to Motor Vehicle Collisions: A National Crash Data-Based Study. Healthcare (Basel). 9(3):273.
- Hauff NJ, et al. 2017. Cumulative trauma and partner conflict predict post-traumatic stress disorder in postpartum African American women. J Clin Nurs, 26(15-16):2372-2383.
- Huls CK, et al. 2018. Trauma in pregnancy. Semin Perinatol, 42:13-20.
- Kallen B, et al.1995. Automobile accidents during pregnancy. Reprod Toxicol, 9:591,
- Leroy-Malherbe V, Bonnier C, Papiernik E, Groos E, Landrieu P. 2006. The association between developmental handicaps and traumatic brain injury during pregnancy: an issue that deserves more systematic evaluation. Brain Inj, 20(13-14):1355–65.
- Lipson AH. 1990. Trauma and intrauterine amputation/constriction rings/syndactyly. Human/animal model correlation. Teratology, 42:330.
- Luley T, et al. 2013. Perinatal implications of motor vehicle accident trauma during pregnancy: identifying populations at risk. Am J Obstet Gynecol, 208(6): 466.e1-5.
- Muench MV, et al. 2004. Kleihauer-betke testing is important in all cases of maternal trauma. J Trauma; 57(5):1094-8.
- Murphy NJ, Quinlan JD, 2014. Trauma in pregnancy: assessment, management, and prevention. Am Fam Physician, 15;90(10):717-22.
- Munter DW, Faleski EJ. 1989. Blunt scrotal trauma: emergency department evaluation and management. Am J Emerg Med, 7:227-34.
- Nelson DB, et al. 2003. Violence does not influence early pregnancy loss. Fertil Steril. 80:1205–1211.
- Safdari, M., Safdari, Z., & Pishjoo, M. 2018. Intrauterine Fetal Traumatic Brain Injury Following Motor Vehicle Accident; A Case Report and Review of the Literature. Bulletin of emergency and trauma, 6(4), 372–375.
- Normann A., et al. 2020. Intimate Partner Violence and Breastfeeding: A Systematic Review. BMJ Open, 10(10):e034153.
- Sakamoto J, et al. 2019. Trauma in pregnancy. Emergency Medicine Clinics of North America 37(2):317-338.
- Shah PS, Shah J. 2010. Knowledge Synthesis Group on Determinants of Preterm/LBW Births. Maternal exposure to domestic violence and pregnancy and birth outcomes: a systematic review and meta-analyses. J Womens Health (Larchmt), 19(11):2017-31.
- Smith KA, Bryce S. 2013. Trauma in the pregnant patient: an evidence-based approach to management. Emerg Med Pract, 15(4):1-18.

- Tinker SC, et al. 2011. Maternal injuries during the periconceptional period and the risk of birth defects, National Birth Defects Prevention Study, 1997–2005. Paediatr Perinat Epidemiol, 25(5):487-96.
- van der Knoop BJ, et al. 2015. Effect of (minor or major) maternal trauma on fetal motility: A prospective study. Early Hum Dev, 91: 511-517.
- van der Knoop BJ, et al. 2017. Trauma in pregnancy, obstetrical outcome in a tertiary centre in the Netherlands. J Matern Fetal Neonatal Med, 11: 1-11.
- Vaajala, M., et al. 2023. Previous traumatic brain injury is associated with an increased odds for gestational diabetes: a nationwide register-based cohort study in finland. Acta Diabetol, 60(10), 1399–1404.
- Yu H, et al. 2018. Association of intimate partner violence during pregnancy, prenatal depression, and adverse birth outcomes in Wuhan, China. BMC Pregnancy Childbirth, 18(1):469.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2026.

Physical Trauma

Selected References:

- Amaral De Lara IC, et al. 2025. Association of prenatal exposure to antiseizure medication with risk of autism: a systematic review and meta-analysis. Seizure; 130:41-47.
- Adrade C. 2024. Epilepsy, antiepileptic drugs, and adverse pregnancy outcomes, 2: Major congenital malformations with antiepileptic drug monotherapy. J Clin Psychiatry; 85(3):24f15432.
- Artama M, et al. 2006. Antiepileptic drug use and birth rate in patients with epilepsy-a population-based cohort study in Finland. Hum Reprod; 21:2290-2295.

- Battino D, et al. 2024. Risk of major congenital malformations and exposure to antiseizure medication monotherapy. JAMA Neurol; 82(5):481-489.
- Bech LF, et al. 2018. In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring. J Neurol Neurosurg Psychiatry; 89:1324–1331.
- Birnbaum AK, et al. 2020. Antiepileptic drug exposure in infants of breastfeeding mothers with epilepsy. JAMA Neurol; 77(4):441-450.
- Bjork M-H, et al. 2022. Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability. JAMA Neurology; 79(7):672-681.
- Blotière PO, et al. 2019. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology; 93(2):e167-e80.
- Blotière PO, et al. 2020. Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study. BMJ Open; 10(6):e034829.
- Bruno MK, Harden CL. 2002. Epilepsy in pregnant women. Curr Treat Options Neurol; 4(1):31-40.
- Bülau P, et al. 1988. Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother. Eur J Clin Pharmacol; 34:311–313.
- Chen CY, et al. 2017. In utero oxcarbazepine exposure and neonatal abstinence syndrome: Case report and brief review of the literature. Pharmacotherapy; 37:e71–e5.
- Christensen J, et al. 2015. Apgar-score in children prenatally exposed to antiepileptic drugs: a population-based cohort study. BMJ Open; 5(9):e007425.
- Cohen JM, et al. 2019. Anticonvulsant mood stabilizer and lithium use and risk of adverse pregnancy outcomes. J Clin Psychiatry; 80(4).
- Cohen JM, et al. 2023. Comparative safety of antiseizure medication monotherapy for major malformations. Ann Neurol; 93(3):551-562.
- Daugaard CA, et al. 2020. Association of prenatal exposure to valproate and other antiepileptic drugs with intellectual disability and delayed childhood milestones. JAMA Netw Open; 3(11):e2025570.
- Dreier JW et al. 2023. Prenatal exposure to antiseizure medication and incidence of childhood- and adolescence-onset psychiatric disorders. JAMA Neurology; 80(6):568-577.
- Eisenschenk S. 2006. Treatment with oxcarbazepine during pregnancy. Neurologist; 12(5):249-254.
- Friis ML, et al. 1993. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand; 87(3):224-227.
- Gentile S. 2003. Oxcarbazepine in pregnancy and lactation. Clin Drug Investig; 23:687.
- Guo Y, et al. 2021. A comparative study of the effects of valproate and oxcarbazepine on sexual function, sperm quality, and sex hormones in males with epilepsy. Biomed Res Int; 2021:6624101.
- Hvas CL, et al. 2000. Epilepsy and pregnancy: effect of antiepileptic drugs and lifestyle on birthweight. Br J Obstet Gynaecol; 107:896-902.
- Hernandez-Diaz S, et al. 2025. Use of antiseizure medications early in pregnancy and the risk of major malformations in the newborn. Neurology; 105(3):e213786.
- Honybun E, et al. Neurodevelopmental and functional outcomes following in utero exposure to antiseizure medication: a systematic review. Neurology; 102(8)e209175.
- Isojarvi JI, et al. 2004. Effect of epilepsy and antiepileptic drugs on male reproductive health. Neurology; 62:247-253.
- Jacobsen PE, et al. 2014. Prenatal exposure to antiepileptic drugs and dental agenesis. PLoS One; 9(1):e84420.
- Johnson K, et al. 2021. Retrospective Analysis of Oxcarbazepine in Pregnant Women With Substance Use Disorders: Focus on Safety. Journal of Pharmacy Practice; 34(1):28-34.
- Kaaja E, et al. 2003. Major malformations in offspring of women with epilepsy. Neurology; 60:575-579.
- Kim HK, et al. 2026. Prenatal Exposure to Antiseizure Medications and the Risk of Congenital Anomalies: A Nationwide Population-Based Study in South Korea. Neurology; 106(1):e214350.

- Lloyd P, et al. 1994. Clinical Pharmacology and Pharmacokinetics of Oxcarbazepine. Epilepsia; 35(s3).
- Luef G, et al. 2009. Oxcarbazepine treatment in male epilepsy patients improves pre-existing sexual dysfunction. Neurologica; 119(2):94-99.
- Lutz UC, et al. 2007. Oxcarbazepine treatment during breast-feeding: a case report. J Clin Psychopharmacol; 27:730–732.
- Meischenguiser R, et al. 2003. Major malformations in offspring of women with epilepsy. [Letter] Neurology; 61:1631.
- Meischenguiser R, et. al. 2004. Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy Behav; 5:163-167.
- Miller M, et al. 2003. Major malformations in offspring of women with epilepsy. [Letter] Neurology; 61:1631.
- Mølgaard-Nielsen D, Hviid A. 2011. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA; 305(19):1996-2002.
- Montouris G. 2005. Safety of the newer antiepileptic drug oxcarbazepine during pregnancy. Curr Med Res Opin; 21:693-701.
- Novartis. 2020. Trileptal® Prescribing Information. Available at URL: https://www.novartis.us/sites/www.novartis.us/files/trileptal.pdf.
- Ohman I, et al. 2009. Pharmacokinetics of oxcarbazine in neonatal period and during lactation. Epilepsia; 50(Suppl. 4):238. Abstract.
- Rolnitsky A, et al. 2013. In utero oxcarbazepine and a withdrawal syndrome, anomalies, and hyponatremia. Pediatr Neurol; 2013;48(6):466-468.
- Supernus Pharmaceuticals. 2018. Otexllar XR® Prescribing Information. Available at URL: https://www.oxtellarxrhcp.com/assets/OxtellarXRPrescribingInformation.pdf.
- Straub L, et al. 2026. Prenatal antiseizure drug exposure and risk of neurodevelopmental disorders in children: population based cohort study. BMJ; 392:e085725.
- The Centers for Disease Control and Prevention (CDC). 2025. Folic Acid: Sources and Recommended Intake. Available at https://www.cdc.gov/folic-acid/about/intake-and-sources.html [Accessed 03/2026].
- Tomson T, et al. 2015. Antiepileptic drugs and intrauterine death: A prospective observational study from EURAP. Neurology; 85: 580-588.
- Tomson T, et al. 2018. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol; 17(6):530-538.
- Trivedi M, et al. 2018. Spontaneous fetal loss in women with epilepsy: prospective data from pregnancy registry in India. Epilepsy Research; 146:50-53.
- Vajda F, et al. 2018. Anti-epieptic drug exposure and risk of foetal death in utero. Acta Neurol Scand; 137(1):20-23.
- Veiby G, et al. 2014. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol; 261:579-588.
- Videman M, et al. 2016. Evidence for spared attention to faces in 7-month-old infants after prenatal exposure to antiepileptic drugs. Epilepsy Behav; 64(Pt A):62-68.
- Weston J, et al. 2016. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev; 11(11):CD010224.
- Wu D, et al. 2018. The effects of oxcarbazepine, levetiracetam, and lamotrigine on semen quality, sexual function, and sex hormones in male adults with epilepsy. Epilepsia; 59(7):1344-1350.
- Yin X, et al. 2022.Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy. CNS Neurosci Ther; 28(5):658-666.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2026.

Physical Trauma

Selected References:

- Gallagher M. 2018. Exposure to Dihyroxyacetone in Sunless Tanning Products. Understanding the Risks. J Dermatol Nurses Assoc. 10(1)11-17.
- Meadows M. 2003. Don’t be in the dark about tanning. FDA Consumer Magazine, 37:6.
- Turner J et al. 2023. In search of the perfect tan: Chemical activity, biological effects, business considerations, and consumer implications of dihydroxyacetone sunless tanning products. J Cosmet Dermatol. 22(1)79-88.
- United States Food and Drug Administration (FDA). 2022. Modernization of Cosmetics Regulation Act of 2022 (MoCRA). Available at https://www.fda.gov/cosmetics/cosmetics-laws-regulations/modernization-cosmetics-regulation-act-2022-mocra.
- United States Food and Drug Administration (FDA). 2024. Sunless tanners and bronzers. Available at https://www.fda.gov/cosmetics/cosmetic-products/sunless-tanners-bronzers
- Yourick JJ, et al. 2004. Fate of chemicals in skin after dermal application: Does the in vitro skin reservoir affect the estimate of systemic absorption? Toxicol Appl Pharmacol, 195:309-320.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2026.

Physical Trauma

Selected References:

- Atluru S, et al. 2024. Naltrexone Compared With Buprenorphine or Methadone in Pregnancy: A Systematic Review. Obstet Gynecol. 143(3):403-410.
- Bello JK. 2024. Pregnancy Rates Among Women Treated with Medication for Opioid Use Disorder. J Gen Intern Med. 39(8):1342-1348.
- Blandthorn J, et al. 2018. Managing opioid overdose in pregnancy with take-home naloxone. Aust N Z J Obstet Gyneacol. 58(4):460-462.
- Caritis SN, Venkataramanan R. 2020. Naltrexone use in pregnancy: a time for change. Am J Obstet Gynecol. 222(1):1-2.
- Debelak K, et al. 2013. Buprenorphine + Naloxone in the treatment of opioid dependence during pregnancy-initial patient care and outcome data. Am J Addict. 22(3):252-254.
- Flannagan KS, et al. 2020. Prescription opioid use among populations of reproductive age: effects on fertility, pregnancy loss, and pregnancy complications. Epidemiol Rev. *42*(1): 117-133.
- Gawronski KM, et al. 2014. Neonatal outcomes following in utero exposure to buprenorphine/naloxone or methadone. SAGE Open Med. 2:2050312114530282.
- Goshgarian G, et al. Prenatal Buprenorphine/Naloxone or Methadone Use on Neonatal Outcomes in Michigan. Cureus.*14*(8):e27790.
- Griffiths S, et al. 2021. Use of injectable opioid agonist therapy in a in-patient setting for a pregnant patient with opioid use disorder: A case report. J Addict Med. *15*(5):435-438.
- Jones HE, Kraft WK. 2019. Analgesia, Opioids, and Other Drug Use During Pregnancy and Neonatal Abstinence Syndrome. Clin Perinatol. 46(2):349-366.
- Jansson LM, et al. 2024. Buprenorphine-Naloxone Maintenance and Lactation. J Hum Lact. *40*(1): 113-119.
- Jumah NA, et al. 2016. Observational study of the safety of buprenorphine+naloxone in pregnancy in a rural and remote population. BMJ Open. 6(10):e011774.
- Kanervo M, et al. 2023. Buprenorphine-naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder. Acta Obstet Gynecol Scand. 102(3): 313-322.
- Kanervo M, et al. 2024. Intrauterine exposure to maternal opioid maintenance treatment and associated risk factors may impair child growth. Acta Paediatr. 113(7):1579-1591.
- Kanervo MM, et al. 2025. Neurodevelopmental challenges at age four following fetal exposure to maternal opioid maintenance treatment. Pediatr Res. 98(5):1737-1745.
- Link HM, et al. 2020. Buprenorphine-naloxone use in pregnancy: a systematic review and metaanalysis. Am J Obstet Gynecol MFM. 2(3):100179.
- Link, HM, et al. 2021. Buprenorphine-naloxone use in pregnancy: a subgroup analysis of medication to treat opioid use disorder. American journal of obstetrics & gynecology MFM. *3*(5): 100369.

- Mantri S, et al. 2024. Neurobehavioral outcomes of infants exposed to buprenorphine-naloxone compared with naltrexone during pregnancy. Early Hum Dev. 194:106051.
- Mitchell C, et al. 2020. Management of dependent use of illicit opioids. BMJ 368:m710.
- Müller S, et al. 2023. Treatment of chronic nodular prurigo with intravenous naloxone during pregnancy. Journal of the Eur Acad Dermatol Venereol. *37*(7): e912-e913.
- Mullins N, et al. 2020. Buprenorphine and naloxone versus buprenorphine for opioid use disorder in pregnancy: a cohort study. J Addict Med. 14(3):185-192.
- Nechanska B, et al. 2018. Neonatal outcomes after fetal exposure to methadone and buprenorphine: national registry studies from the Czech Republic and Norway. Addiction. 113(7):1286-1294.
- Nguyen L, et al. 2018. Treating Women with Opioid Use Disorder during Pregnancy in Appalachia: Initial Neonatal Outcomes Following Buprenorphine+Naloxone Exposure. Am J Addict. 27(2):92-96.
- Ordean A, Tubman-Broeren, M. 2023. Safety and efficacy of buprenorphine-naloxone in pregnancy: a systematic review of the literature. Pathophysiology. *30*(1): 27-36.
- Piske M, et al. 2021. Opioid use disorder and perinatal outcomes. Pediatrics. 148(4):e2021050279.
- Preston KL, et al. 1990. Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug Alcohol Depend. 25(1):27-34.
- Straub L, et al. 2024. Comparative Safety of In Utero Exposure to Buprenorphine Combined With Naloxone vs Buprenorphine Alone. JAMA.332(10):805-816.
- Wiegand SL, et al. 2016. Naloxone and Metabolites Quantification in cord Blood of Prenatally Exposed Newborns and Correlations with Maternal Concentrations. AJP Rep. 6(4)e385-e390.
- Zelner I, et al. 2015. Acute Poisoning During Pregnancy: Observations from the Toxicology Investigators Consortium. J Med Toxicol. 11(3):301-308.

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2026.

Physical Trauma

Selected References

- Ankarfeldt MZ, et al. 2021. Exposure to duloxetine during pregnancy and risk of congenital malformations and stillbirth: A nationwide cohort study in Denmark and Sweden. PLOS Medicine, 18(11):e1003851.
- Ankarfeldt MZ, et al. 2023. Duloxetine exposure during pregnancy and the risk of offspring being born small for gestational age or prematurely: A nationwide Danish and Sweden safety study. Drugs Real World Outcomes, 10(1):69-81.
- Bellantuono C, et al. 2015. The safety of serotonin-noradrenaline reuptake inhibitors (SNRIs) in pregnancy and breastfeeding: a comprehensive review. Hum Psychopharmacol, 30(3):143-51.
- Gentile S, et al. 2019. Managing fibromyalgia syndrome in pregnancy no bridges between USA and EU. Archives of Women's Mental Health, 22(6):711-721.
- Hoog SL, et al. 2013. Duloxetine and pregnancy outcomes: safety surveillance findings. International Journal of Medical Sciences. 10(4):413-419.
- Huybrechts KF, et al. 2020 Maternal and fetal outcomes following exposure to duloxetine in pregnancy: cohort study. BMJ 368:m237.
- Kallen B, et al. 2013. The use of central nervous system active drugs during pregnancy. Pharmaceuticals. 6(10):1221-1286.
- Kjaersgaard MI, et al. 2013. Prenatal antidepressant exposure and risk of spontaneous abortion – a population-based study. PLoS One, 8(8):e72095.
- Lassen D, et al. 2016. First-Trimester Pregnancy Exposure to Venlafaxine or Duloxetine and Risk of Major Congenital Malformations: A Systematic Review. Basic & clinical pharmacology & toxicology. 118(1):32-6. doi:10.1111/bcpt.12497.
- Liu D, et al. 2025. Uncovering safety signals of duloxetine: Real-world evidence from the FAERS database. J Affect Disord. 388:119517. doi:10.1016/j.jad.2025.119517
- Marks C, et al. 2021.Comparing newborn outcomes after prenatal exposure to individual antidepressants: a retrospective cohort study. Pharmacotherapy 41(11):907-914.
- Punjani N, et al. 2021. Impact of duloxetine on male fertility: A randomized controlled clinical trial. Andrologia, 53(10):e14207.
- Richendrfer H, et al. 2018. Cluster analysis profiling of behaviors in zebrafish larvae treated with antidepressants and pesticides. Neurotoxicology Teratology, 69:54-62.

¿Preguntas? Llame al 866.626.6847 | Texto 855.999.3525 | Correo electrónico o chat en MotherToBaby.org .

Descargo de responsabilidad: las hojas informativas de MotherToBaby están destinadas a fines de información general y no deben reemplazar los consejos de su proveedor de atención médica. MotherToBaby es un servicio de la Organización sin fines de lucro de Especialistas en Información de Teratología (OTIS). Copyright de OTIS, 1 de marzo de 2026.